Ipilimumab-induced hypophysitis: early Australian experience

Sunita M C De Sousa, Georgina V Long and Katherine T Tonks
Med J Aust 2014; 201 (4): . || doi: 10.5694/mja14.00803
Published online: 18 August 2014

To the Editor: We report two men aged in their 60s receiving ipilimumab for metastatic melanoma who presented with headache and constitutional symptoms after the third 3-weekly dose, and were diagnosed with ipilimumab-induced hypophysitis. Ipilimumab is a monoclonal antibody that binds to cytotoxic T lymphocyte-associated antigen 4, resulting in T-cell activation and proliferation. It was the first therapy to yield a survival benefit in metastatic melanoma,1 but at the cost of frequent immune-related adverse events.2

  • Sunita M C De Sousa1
  • Georgina V Long2
  • Katherine T Tonks3

  • 1 Department of Endocrinology, St Vincent's Hospital, Sydney, NSW.
  • 2 Melanoma Institute Australia, Sydney, NSW.
  • 3 Diabetes and Metabolism Division, Garvan Institute of Medical Research, Sydney, NSW.



We thank Diana Adams of Macarthur Cancer Therapy Centre at Campbelltown Hospital, Sydney, who shared in patient care.

Competing interests:

Georgina Long is a consultant adviser to Bristol-Myers Squibb, Merck, Amgen, GlaxoSmithKline, Novartis and Roche.


remove_circle_outline Delete Author
add_circle_outline Add Author

Do you have any competing interests to declare? *

I/we agree to assign copyright to the Medical Journal of Australia and agree to the Conditions of publication *
I/we agree to the Terms of use of the Medical Journal of Australia *
Email me when people comment on this article

Responses are now closed for this article.